| Australian Foundation Investment Company Limited (AFI) ORDINARY FULLY PAID |
Financials |
$8,270 |
Update - Notification of buy-back - AFI
|
27 Feb 2026 8:50AM |
$6.920 |
$6.620 |
fallen by
4.34%
|
|
| AML3D Limited (AL3) ORDINARY FULLY PAID |
Industrials |
$114 |
Investor Presentation
|
27 Feb 2026 8:50AM |
$0.155 |
$0.205 |
risen by
32.26%
|
|
| Hubify Limited (HFY) ORDINARY FULLY PAID |
Communication Services |
$8 |
HFY 1H FY26 Appendix 4D and Half Year Financial Report
|
27 Feb 2026 8:49AM |
$0.008 |
$0.015 |
risen by
87.50%
|
|
HFY - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue decreased by 7% to $8.3 million due to shedding non-core customers.
- EBITDA improved by 84% to $0.33 million.
- Net loss after tax was $242,555, improved from $422,623.
- Focus on high-value recurring revenue and cost optimization.
- Cash and cash equivalents increased to $3.01 million.
- Significant management change with new CFO, Deepak Nand.
- $250,000 capital raise through a share placement post-reporting period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mesoblast Limited (MSB) ORDINARY FULLY PAID |
Health Care |
$2,835 |
Corporate Presentation and Half Year Financial Results
|
27 Feb 2026 8:49AM |
$2.420 |
$2.190 |
fallen by
9.50%
|
|
MSB - Price-sensitive ASX Announcement
Full Release
Key Points
- Mesoblast received U.S. FDA approval for RYONCIL in December 2024.
- RYONCIL is the first FDA-approved allogeneic mesenchymal stromal cell product.
- RYONCIL launched in April 2025, with a net revenue of US$49 million in H1 FY26.
- Strong gross margin of 93% for RYONCIL with significant R&D investment.
- Successful U.S. commercial launch of RYONCIL boosting profitability.
- Mesoblast anticipates full-year fiscal 2026 Ryoncil® net revenue between US$110 million and US$120 million.
- Phase 3 trials ongoing for rexlemestrocel-L for chronic low back pain.
- REVASCOR® is being developed for chronic heart failure and has shown efficacy in clinical trials.
- Strong financial position with US$130 million cash balance at Dec 31, 2025.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Coles Group Limited (COL) ORDINARY FULLY PAID |
Consumer Staple |
$30,973 |
2026 Half Year Results Presentation
|
27 Feb 2026 8:48AM |
$22.190 |
$23.060 |
risen by
3.92%
|
|
COL - Price-sensitive ASX Announcement
Full Release
Key Points
- Coles Group Limited reported a 14.6% growth in Supermarkets EBIT with strong sales momentum.
- Supermarkets eCommerce sales grew by 27%.
- Coles declared a fully franked interim dividend of 41 cents per share.
- Group sales revenue for the first half of 2026 was $23.6 billion.
- Reported Group EBIT, excluding significant items, was $1,231 million.
- Significant items of $235 million were recorded due to a Federal Court judgment.
- Coles has expanded its partnership with Uber Eats.
- The company achieved the highest rate of monthly DIFOT since December 2020 over the Christmas period.
- The Liquorland banner simplification conversions were completed.
- Coles' partnership with OpenAI to roll out ChatGPT Enterprise to team members was highlighted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 4DMedical Limited (4DX) ORDINARY FULLY PAID |
Health Care |
$2,811 |
Appendix 4D and FY26 Half Year Report
|
27 Feb 2026 8:47AM |
$3.720 |
$4.760 |
risen by
27.96%
|
|
4DX - Price-sensitive ASX Announcement
Full Release
Key Points
- 4DMedical's operating revenue for H1 FY26 was $2.9 million with a gross margin exceeding 90%.
- The company achieved FDA clearance and CMS reimbursement for their CT:VQ™ imaging technology.
- CT:VQ™ was rapidly adopted by major U.S. Academic Medical Centers.
- The company reported an 18% reduction in net loss compared to the previous year.
- A strategic investment of $10 million from Pro Medicus was secured to support commercialisation efforts.
- 4DMedical completed a $150 million institutional placement to strengthen their cash position.
- Expanded regulatory approvals were obtained in Canada and New Zealand, with further applications in Europe and Australia.
- 4DMedical experienced a 43% global growth in SaaS product delivery sites.
- Julian Sutton was appointed as the new Chief Financial Officer.
- The company received $1.1 million in non-dilutive funding from the Australian Economic Accelerator Innovate grant program.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| X2M Connect Limited (X2M) ORDINARY FULLY PAID |
Information Technology |
$6 |
Proposed issue of securities - X2M
|
27 Feb 2026 8:47AM |
$0.007 |
$0.004 |
fallen by
42.86%
|
|
| X2M Connect Limited (X2M) ORDINARY FULLY PAID |
Information Technology |
$6 |
Proposed issue of securities - X2M
|
27 Feb 2026 8:46AM |
$0.007 |
$0.004 |
fallen by
42.86%
|
|
| X2M Connect Limited (X2M) ORDINARY FULLY PAID |
Information Technology |
$6 |
$3m capital raise
|
27 Feb 2026 8:46AM |
$0.007 |
$0.004 |
fallen by
42.86%
|
|
X2M - Price-sensitive ASX Announcement
Full Release
Key Points
- X2M announces a two-tranche Placement raising approximately $3.0 million.
- $1.52 million raised in the first tranche; the balance subject to shareholder approval.
- Funds will facilitate entry into the Japanese water market and expansion in Australia.
- Capital raise follows strong performance with 45% revenue growth in H1 FY26.
- Debt reduced significantly from $7.2 million to about $602,000 after the raise.
- Tranche 1 shares will be issued on 5 March 2026, commence trading on 6 March 2026.
- Joint lead managers for the raise are Peak Asset Management and Alpine Capital.
- Free attaching Options for every two Placement Shares issued, subject to approval.
- Company expects continued revenue growth driven by new contracts and market expansions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| OMG Group Limited (OMG) ORDINARY FULLY PAID |
Consumer Staple |
$8 |
Change of Director's Interest Notice
|
27 Feb 2026 8:46AM |
$0.009 |
$0.008 |
fallen by
5.88%
|
|
| Antilles Gold Limited (AAU) ORDINARY FULLY PAID |
Materials |
$41 |
Variation to Project Funding Arrangements-Nueva Sabana, Cuba
|
27 Feb 2026 8:46AM |
$0.015 |
$0.013 |
fallen by
16.67%
|
|
| Novatti Group Limited (NOV) ORDINARY FULLY PAID |
Information Technology |
$15 |
Half Yearly Report and Accounts
|
27 Feb 2026 8:45AM |
$0.027 |
$0.025 |
fallen by
7.41%
|
|
NOV - Price-sensitive ASX Announcement
Full Release
Key Points
- Novatti Group Limited reported a half-year loss after tax of AUD 2.022 million.
- Revenue from international payment services decreased significantly.
- Comprehensive income resulted in a net loss, partially offset by discontinued operations.
- Management changes included the resignation of Killian Murphy and the appointment of new directors.
- Financial statements include profit or loss, changes in equity, and cash flows.
- Compliance with Australian accounting standards was affirmed.
- The auditor's review confirmed adherence to the Corporations Act 2001.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Freehill Mining Limited (FHS) ORDINARY FULLY PAID |
Materials |
$8 |
Option to Acquire Highly Prospective Copper-Gold Projects
|
27 Feb 2026 8:45AM |
$0.003 |
$0.002 |
fallen by
33.33%
|
|
FHS - Price-sensitive ASX Announcement
Full Release
Key Points
- Resource upgrade at Blanco y Negro Deposit in Chile.
- 10% increase in resource tonnes and 60% shift to Indicated category.
- New Indicated Resource: 0.8Mt @ 1.5% Cu, 0.5 g/t Au.
- New Inferred Resource: 0.7Mt @ 1.3% Cu, 0.6 g/t Au.
- Total Resource: 1.5Mt @ 1.4% Cu, 0.5 g/t Au.
- Expressions of interest from third parties to purchase the project.
- Drilling program confirms copper and gold mineralization.
- The deposit is open to the northwest along strike and down dip.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Powerhouse Ventures Limited (PVL) ORDINARY FULLY PAID |
Financials |
$19 |
PVL Half Year Results Presentation
|
27 Feb 2026 8:44AM |
$0.140 |
$0.115 |
fallen by
17.86%
|
|
| QBE Insurance Group Limited (QBE) ORDINARY FULLY PAID |
Financials |
$33,605 |
Notification of cessation of securities - QBE
|
27 Feb 2026 8:43AM |
$21.670 |
$22.370 |
risen by
3.23%
|
|
| Guzman Y Gomez Limited (GYG) ORDINARY FULLY PAID |
Consumer Discretionary |
$1,952 |
Update - Notification of buy-back - GYG
|
27 Feb 2026 8:43AM |
$19.400 |
$19.280 |
fallen by
0.62%
|
|
| Nanosonics Limited (NAN) ORDINARY FULLY PAID |
Health Care |
$1,123 |
Update - Notification of buy-back - NAN
|
27 Feb 2026 8:43AM |
$3.250 |
$3.700 |
risen by
13.85%
|
|
| Acusensus Limited (ACE) ORDINARY FULLY PAID |
Information Technology |
$270 |
Cleansing Notice
|
27 Feb 2026 8:43AM |
$1.800 |
$1.600 |
fallen by
11.11%
|
|
| Mesoblast Limited (MSB) ORDINARY FULLY PAID |
Health Care |
$2,835 |
Half Year Report and Accounts (including Appendix 4D)
|
27 Feb 2026 8:42AM |
$2.420 |
$2.190 |
fallen by
9.50%
|
|
MSB - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant revenue increase due to the launch of Ryoncil®.
- Net loss reduced by 16% compared to the previous year.
- Ryoncil® approved by the FDA for pediatric SR-aGVHD.
- New credit-line facility adopted to restructure existing debt.
- Continued development of allogeneic cellular therapies for severe inflammatory conditions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| OMG Group Limited (OMG) ORDINARY FULLY PAID |
Consumer Staple |
$8 |
Cleansing Notice
|
27 Feb 2026 8:42AM |
$0.009 |
$0.008 |
fallen by
5.88%
|
|
| Ansell Limited (ANN) ORDINARY FULLY PAID |
Health Care |
$3,797 |
Update - Notification of buy-back - ANN
|
27 Feb 2026 8:42AM |
$32.330 |
$26.760 |
fallen by
17.23%
|
|
| NOVONIX Limited (NVX) ORDINARY FULLY PAID |
Information Technology |
$228 |
Application for quotation of securities - NVX
|
27 Feb 2026 8:42AM |
$0.335 |
$0.265 |
fallen by
20.90%
|
|
| AF Legal Group Ltd (AFL) ORDINARY FULLY PAID |
Industrials |
$15 |
Appendix 4D & Half Year Financial Report
|
27 Feb 2026 8:41AM |
$0.170 |
$0.160 |
fallen by
5.88%
|
|
AFL - Price-sensitive ASX Announcement
Full Release
Key Points
- Record half-year revenue of $17.8 million, a 40% increase from the prior year.
- Normalized net profit before tax increased by 125% to $1.263 million.
- Project Titan and Armstrong Legal acquisition contributed significantly to growth.
- Total expenses increased by 12% to $16.3 million.
- Dividends of $850,000 were declared and paid.
- Cash position at $2.8 million.
- Expansion in family law services and team growth.
- Positive financial outlook with expected continued growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Coles Group Limited (COL) ORDINARY FULLY PAID |
Consumer Staple |
$30,973 |
2026 Half Year Results Release
|
27 Feb 2026 8:39AM |
$22.190 |
$23.060 |
risen by
3.92%
|
|
COL - Price-sensitive ASX Announcement
Full Release
Key Points
- Supermarkets sales revenue increased by 3.6%
- Liquor sales revenue declined by 3.2%
- Group EBITDA excluding significant items rose by 7.8%
- Group EBIT excluding significant items increased by 10.2%
- Fully franked interim dividend of 41 cents per share declared
- Expansion of eCommerce and partnership with Uber Eats
- Increased retail media income by 10.3%
- Significant investment in property, plant, and equipment
- Market challenges in Liquor segment
- Customer value focus with price reductions
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| WAM Alternative Assets Limited (WMA) ORDINARY FULLY PAID |
Financials |
$194 |
Dividend/Distribution - WMA
|
27 Feb 2026 8:39AM |
$1.025 |
$0.985 |
fallen by
3.90%
|
|
WMA - Price-sensitive ASX Announcement
Full Release
Key Points
- Announcement date is February 27, 2026.
- Dividend amount is AUD 0.03 per security.
- Record date is April 15, 2026.
- Ex-dividend date is April 14, 2026.
- Payment date is April 29, 2026.
- Dividend is 60% franked with a 30% corporate tax rate.
- A full DRP is applicable with a lodgement deadline of April 17, 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
